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Abstract 
 
Recent evidence on maintenance administration of epoetin beta pegol, a continuous 
erythropoiesis receptor activator (CERA), in dialysis patients shows the clinical benefit 
of bi-weekly administration (Q2W) in improving hematopoiesis and iron use efficiency. 
We undertook a single-center observational study of 33 Japanese maintenance dialysis 
patients, whose anemia had been kept stable through weekly administration (Q1W) of 
darbepoetin (DA), to evaluate the effectiveness of CERA Q2W switched from DA in 
maintaining hemoglobin (Hb) levels over a 12-month period. The target Hb level was 
10.0–12.0 g/dL. Throughout the 12-month period, the mean Hb was stably maintained 
at 10.5–10.8 g/dL, 69.7–87.9% of the patients achieving the target Hb level. The mean 
CERA dose was within the range of 62.9–78.8 μg/2 weeks. The average CERA dose 
adjustment frequency after switching was low at 0.42–0.67 times/3 months. In both 
subgroups stratified by the DA dose prior to the switch, Hb levels were kept stable 
during CERA administration; however, in the low-dose group (10–20 μg/week of DA), 
the CERA and iron doses decreased over time, whereas in the high-dose group (30–60 
μg/week of DA) they remained unchanged. CERA Q2W achieved long-term successful 
anemia management in Japanese maintenance dialysis patients after switching from 
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DA Q1W. CERA dose was adjusted based on an overall consideration of past changes in 
Hb levels, erythropoiesis-stimulating agent (ESA) and iron doses. Subgroup analysis 
showed the CERA dose in the low-dose group decreased continuously, due possibly to a 
long-term improvement in iron use efficiency. 
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Introduction 
 
Epoetin beta pegol is a continuous erythropoiesis receptor activator (CERA) that has 
the longest half-life of any erythropoiesis-stimulating agent (ESA), extending from 5 to 
10 times longer than the half-lives of other conventional ESAs [1]. Frequent ESA 
administration to hemodialysis patients is an onerous task for medical staff, and CERA 
may help to mitigate this burden [2]. CERA also acts to enhance iron mobilization from 
body stores during hematopoiesis, through inhibiting hepcidin-25, suggesting that it 
may provide more efficient iron mobilization compared with darbepoetin alfa (DA), 
which is often used to treat hemodialysis patients [3]. 
The dose interval for the maintenance administration of CERA to dialysis patients 
approved by Japanese regulatory agencies is once every 4 weeks (Q4W); however, this 
can be adjusted to once every 2 weeks (Q2W) if hemoglobin (Hb) levels are not 
maintained within the target range. Although clinical studies have confirmed that 
target Hb levels are kept stable through the administration of CERA Q4W or once 
monthly [4, 5], recent studies have suggested that Q2W administration may be 
clinically useful in maintaining Hb levels with greater reliability than Q4W 
administration [6], enabling reduction of CERA dose [7, 8], improving iron use efficiency 
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[7,9,10], and increasing erythropoiesis [6]. The guidelines on the management of renal 
anemia, published by the Japanese Society for Dialysis Therapy (JSDT) as the 2015 
edition, suggest that CERA Q2W may be more effective than Q4W [11]. 
In terms of patients switched from another ESA to CERA Q2W, the STRIATA trial, a 
Phase III international joint trial of CERA, found that Hb levels were kept stable for 12 
months after patients were switched from DA once weekly (Q1W) or Q2W to CERA Q2W  
[12]. A number of Japanese hospitals have also published reports of patients switching 
from DA to CERA Q2W or twice a month, but most of these reports have only described 
a short monitoring period following the switch [13-16]. Evidence is still lacking on how 
to use CERA and iron for long-term reliable anemia management following the switch 
from DA. 
We undertook a single-center observational study in Japan of 33 Japanese 
maintenance dialysis patients whose anemia had been kept stable through DA Q1W 
and who were switched to CERA Q2W, and we evaluated its effectiveness in 
maintaining hemoglobin (Hb) levels over a 12-month period and methods of anemia 
management, with a focus on CERA dose adjustment and iron replacement.  
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Methods 
 
Patients 
This was a retrospective cohort observational study undertaken at a single center in 
Japan. The study participants were 33 patients, who met all of the following criteria: (1) 
undergoing outpatient maintenance dialysis three times a week; (2) had switched from 
intravenous DA Q1W (10 g to 60 g) to CERA Q2W between July 21, 2014 and April 1, 
2016; (3) had been receiving intravenous DA Q1W (10 g to 60 g) for at least 3 months 
immediately prior to the switch to CERA, during which period the Hb levels had been 
maintained within a range from 9.0 g/dL to 12.0 g/dL and; (4) had been undergoing 
dialysis for 1 year when they were switched to CERA. 
All patients enrolled in this study have given their informed consent, which has been 
approved by the Ethics Committee of the International Kidney Evaluation Association 
Japan (No. 2901), and this protocol has been found acceptable by them. 
 
CERA dosage, administration, and iron replacement 
All the study participants were switched from intravenous DA Q1W to intravenous 
CERA Q2W and were monitored for 12 months following the switch. The initial CERA 
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Q2W dose was calculated on the basis of the DA Q1W dose prior to the switch in 
accordance with the CERA formulation specifications as DA 10 g Q1W = CERA 25 g 
Q2W, DA 15 g – 20 g Q1W = CERA 50 g Q2W, DA 30 g Q1W = CERA 75 g Q2W, DA 
40 g Q1W = CERA 100 g Q2W, and DA 60 g Q1W = CERA 150 g Q2W, with an 
increase or decrease of one level permitted in light of Hb levels during the 3 months 
prior to the switch. CERA dose was adjusted, as necessary, to maintain Hb levels within 
the target range (10.0 g/dL to 12.0 g/dL), based on the blood test data described below. 
Following the JSDT guideline recommendations for the management of renal anemia 
[17], iron replacement was started when serum ferritin level is 100 ng/mL and 
transferrin saturation (TSAT) level is 20%. Iron was administered as intravenous 
saccharated ferric oxide 40 mg once a week, and the procedure involved reviewing its 
administration after a 5-week course had been completed. 
 
Blood sampling, assessments, and subgroup analysis 
A complete blood count (white blood cells (WBC), red blood cells (RBC), Hb, and 
hematocrit (Ht)) was performed once a week during the 3 months prior to the switch 
and the following 12 months of CERA administration, for the purposes of anemia 
management and iron evaluation. Iron metabolism markers (serum iron, unsaturated 
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iron binding capacity, serum ferritin, and TSAT), nutritional markers (total serum 
protein, total serum albumin, and cholinesterase), and an inflammatory marker 
(C-reactive protein (CRP)) were also measured once a month. 
The parameters evaluated were Hb levels prior to the CERA switch and during CERA 
administration, CERA dose, iron dose, iron metabolism markers, nutritional markers, 
an inflammatory marker, and dialysis indicators (protein catabolic rate (PCR) and Kt/V 
dose). The iron dose was calculated as the dose per week during the 3 months prior to 
the switch to CERA and during months 1 to 3, 4 to 6, 7 to 9, and 10 to 12 following the 
switch. The target Hb level achievement rate during CERA administration was also 
evaluated. The frequency with which CERA dose was adjusted (increased or decreased) 
in months 1 to 3, 4 to 6, 7 to 9, and 10 to 12 following the switch was also calculated and 
evaluated. 
The participants were divided into 2 subgroups, depending on whether they had been 
receiving a low dose (10, 15, or 20 g/week) or a high dose (30, 40, or 60 g/week) of DA 
prior to the switch, and their Hb levels, CERA dose, iron dose, frequency of CERA dose 
adjustment, and various markers were investigated. To analyze changes in iron 
metabolism dynamics following the switch to CERA in the low-dose and high-dose 
groups, we also investigated correlations between the magnitude of changes in any 
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parameters including CERA and iron doses that exhibited changes over time during the 
12 months following the switch. 
 
Statistical analysis 
Data were expressed as means  standard deviations. Changes over time were 
analyzed using a Wilcoxon signed-rank test. Comparisons between the low-dose and 
high-dose groups were made using a Wilcoxon rank-sum test. Correlations between the 
magnitude of changes in parameters that exhibited changes over time during the 12 
months following the switch were evaluated using a Spearman rank correlation 
analysis. For all tests, p0.05 was regarded as statistically significant. 
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Results 
 
Participant characteristics 
Table 1 shows the characteristics of the 33 study participants, who comprised 15 men 
and 18 women with a mean age of 67.7  11.5 years. The mean length of dialysis for 
participants was 9.3  7.9 years, involving 14 participants with diabetes-related 
nephropathy, 11 participants with chronic glomerulonephritis, 4 participants with 
nephrosclerosis, 1 participant with polycystic kidney disease, and 3 participants with 
other underlying conditions. 
 
Clinical markers 
Table 2 shows the results of laboratory tests prior to the switch to CERA and during 
CERA administration. The dialysis indicators, PCR and Kt/V, and the nutritional 
markers for total serum protein, serum albumin, and cholinesterase all remained 
extremely stable throughout these periods. Although CRP rose transiently to an 
abnormally high value of 1.0 mg/dL in some participants, there was no significant 
change compared with baseline. None of the iron metabolism markers exhibited any 
marked fluctuation, with no significant change compared with baseline. Mean serum 
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ferritin was maintained in a range between 43.9 ng/dL and 62.8 ng/dL, and mean TSAT 
ranged between 13.9% and 19.9%. 
 
Hb levels, CERA dose, and the frequency of CERA dose adjustment 
Fig. 1a shows monthly changes in mean Hb levels prior to the switch to CERA and 
during CERA administration. Hb levels remained stable throughout these periods, with 
no significant change. The target Hb level achievement rate was maintained within a 
range between 69.7% and 87.9% during CERA administration. 
When converted to one dose/2 weeks, the mean DA dose prior to the switch was 65.2  
29.98 g/2 weeks. The mean CERA dose at the switch was 77.3  30.8 g/2 weeks, with 
the mean initial dose conversion ratio from DA of 1.24  0.33. Following the switch, the 
mean CERA dose was 76.5  36.4 g/2 weeks at 12 weeks, 73.5  38.0 g/2 weeks at 26 
weeks, 65.9  41.8 g/2 weeks at 38 weeks, and 68.2  40.6 g/2 weeks at 50 weeks, with 
no significant change over time throughout the duration of CERA administration 
compared with the dose at the switch (Fig. 1b). 
The total number of times CERA dose was adjusted upward / downward in each 
3-month period of CERA administration following the switch was 5 times / 9 times in 
Months 1 to 3, 8 times / 14 times in Months 4 to 6, 9 times / 11 times in Months 7 to 9, 
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and 9 times / 6 times in Months 10 and 12. The number of dose adjustments per patient 
was 0.42  0.90 times in Months 1 to 3, 0.67  0.82 times in Months 4 to 6, 0.61  0.86 
times in Months 7 to 9, and 0.45  0.71 times in Months 10 to 12, with no significant 
change in these numbers over time (Fig. 1c). 
 
Iron dose 
The mean iron dose per week was 15.8  8.4 mg/week in the 3 months prior to the 
switch, 15.8  9.0 mg/week in Months 1 to 3, 17.7  10.0 mg/week in Months 4 to 6, and 
14.5  11.4 mg/week in Months 7 to 9, with no significant change occurring throughout 
these periods. However, a tendency to decrease was evident in Months 10 to 12, when 
the mean iron dose was 10.7  9.0 mg/week (p=0.051) (Fig. 1d). 
 
Subgroup analysis 
A subgroup analysis based on the DA dose prior to the switch comprised 11 patients in 
the low-dose group and 22 in the high-dose group. 
Fig. 1e shows the monthly mean Hb levels in both groups prior to the switch to CERA 
and during CERA administration. Throughout these periods there were no major 
changes in Hb levels exhibited by either group, though there was a transient significant 
14 
 
increase (p0.05) in the level in the low-dose group at the first month following the 
switch. The target Hb level achievement rates during CERA administration were 
maintained within the range between 59.1% and 81.8% in the high-dose group and 
between 81.8% and 100% in the low-dose group. 
When converted to one dose/2 weeks, the mean DA doses prior to the switch were 33.6 
 6.7 g/2 weeks in the low-dose group and 80.9  23.5 g/2 weeks in the high-dose 
group. The mean CERA doses at the switch were 47.7  17.5 g/2 weeks in the low-dose 
group and 92.0  24.9 g/2 weeks in the high-dose group, with the mean initial dose 
conversion ratio of 1.42  0.48 in the low-dose group, which was significantly higher 
than that of 1.16  0.18 in the high-dose group (p0.05). In the high-dose group, the 
CERA dose did not change significantly throughout the duration of CERA 
administration, but in the low-dose group it tended to decrease over time, and this 
decrease was significant at 32 weeks, and between 38 and 48 weeks following the switch 
(p0.05) (Fig. 1f). The mean CERA dose conversion ratios for the low-dose and high-dose 
groups were 1.36  0.99 and 1.14  0.18, respectively, at 12 weeks following the switch; 
1.14 0.39 and 1.14  0.35, respectively, at 26 weeks; 0.93  0.39 and 1.09  0.47, 
respectively, at 38 weeks; and 1.08  0.48 and 1.06  0.47, respectively, at 50 weeks, with 
no significant difference evident after 12 weeks. 
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There were also differences between the two subgroups in the trends following the 
mean weekly iron doses in each group (Fig. 1g). In the high-dose group, the mean iron 
dose remained stable from 16.1  8.7 mg/week during the 3 months prior to the switch 
to 13.4  8.9 mg/week during Months 10 to 12, with no significant change occurring 
during this period. In the low-dose group, however, it decreased significantly over time, 
from 15.2  8.2 mg/week during the 3 months prior to the switch to 5.3  6.9 mg/week 
during Months 10 to 12 (p0.05). In terms of iron metabolism markers, serum ferritin 
levels remained stable throughout CERA administration, and did not change 
significantly compared with the level at the switch in either group. TSAT also remained 
stable overall in the high-dose group exhibiting transient significant increase at Month 
7 and 12 following the switch (p0.05), while in the low-dose group there was no 
significant change during CERA administration compared with the time of the switch. 
In the low-dose group, there was a significant positive correlation between the change 
in CERA dose during the 12 months following the switch and the change in the mean 
weekly iron dose from the 3 months period prior to the switch to Months 10 to 12 (rS = 
0.71, p0.05). The change in TSAT during the 12 months following the switch was not 
significantly correlated with the change neither in CERA dose nor during the 12 
months. 
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Discussion 
 
Our study findings suggest that in Japanese maintenance hemodialysis patients with 
renal anemia, Hb levels could be kept stable for 12 months after switching from DA 
Q1W to CERA Q2W. The STRIATA study, a phase III international joint study with 
participation from European, Australian, and Canadian institutions, showed that stable 
Hb levels were maintained for 12 months when patients were switched from DA Q1W or 
Q2W to CERA Q2W. [12] While no Japanese facilities participated in the STRIATA 
study, our study targeting Japanese patients revealed the same results as those of the 
STRIATA study, confirming that long-term maintenance administration with CERA 
Q2W after switching from DA Q1W administration was clinically useful for renal 
anemia management after initiating dialysis. In addition, although the conversion 
method used in the present study from pre-switchover DA dosage to CERA initial 
dosage was clearly different to that used in the STRIATA study, Hb levels were stably 
maintained from directly after the switchover, as observed in the STRIATA study. In the 
STRIATA study, conversion was performed in three stages from <40 μg/week of DA to 60 
μg/2 weeks of CERA, 40–80 μg/week of DA to 100 μg/2 weeks of CERA, and >80 μg/week 
of DA to 180 μg/2 weeks of CERA. In the present study, however, conversion was 
performed with more gradual changes, in five stages, to conform to the CERA 
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formulation specifications allowing for use in Japan (DA dosage in the range of 10–60 
μg/week set within the range of 25–150 μg/2 weeks of CERA).  
Dialysis patients treated with short-acting ESAs, who are switched to another ESA, 
may subsequently exhibit transient fluctuations in Hb levels [18-20]. Toida et al. carried 
out a randomized comparative study of Q2W and Q4W administration of CERA in 
patients switched from recombinant human erythropoietin (rHuEPO), and found that 
the Q2W administration maintained stable Hb levels with no decrease following the 
switch [21]. Although CERA greatly reduces blood hepcidin-25 levels after 
administration, its concentration is known to rise again 2 weeks later [22]. CERA Q2W 
suppresses hepcidin-25 in a more sustained manner than Q4W, improving iron 
metabolism and permitting more effective iron use in erythropoiesis [9, 10]. Therefore, 
this dosage regimen may be appropriate for maintaining stable Hb levels, not only after 
switching from DA but also during long-term maintenance administration. Hb 
variability in dialysis patients may elevate the risk of cerebrovascular and 
cardiovascular disease [23, 24], infection [23, 24], and death [25, 26], and it is important 
to adopt an ESA dosing strategy that can maintain stable Hb levels within the target 
range over the long term. 
In terms of CERA dose adjustments, stabilizing CERA blood concentration takes 
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approximately 6 weeks [27]; therefore, frequent dose adjustments are undesirable, 
particularly immediately following the switch. We measured Hb levels together with 
RBC, WBC and Ht levels (a complete blood count) once a week. The main purpose of 
these frequent measurements was for early detection of the appearance or deterioration 
of anemia due to causes other than renal anemia, such as gastrointestinal bleeding, as 
well as other abnormalities such as infection, and they were not performed as a basis for 
frequent CERA dose adjustments. An overall determination on adjusting CERA dose 
was made each time CERA was administered, taking into account not only the monthly 
assessments of inflammation, nutritional status, and iron status, but also past changes 
in Hb levels, ESA dose, and iron dose over the previous year.  
Regarding the optimum frequency of Hb monitoring and ESA dose adjustment for 
anemia management in dialysis patients, a retrospective analysis of 3-year 
observational data from 436,442 dialysis patients treated with the short-acting ESA 
epoetin alfa in 2,763 institutions in the United States found that the greater the 
frequency of Hb monitoring and ESA dose adjustment, the lower the Hb variability [28]. 
Gaweda et al. argued that more frequent Hb monitoring may enable more appropriate 
ESA dose adjustment by reducing the effects of short-term factors such as interdialytic 
weight gain and measurement error on the magnitude of Hb variability, concluding that 
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an optimum Hb monitoring frequency seems to be once a week [29]. However, Kalicki et 
al. pointed out that frequent ESA dose adjustment on the basis of the most recent 
short-term test results may result in unstable anemia management, and that it is 
important to take account of the lifespan of red blood cells in dialysis patients, which is 
approximately 2 to 4 months, when determining the frequency of ESA dose adjustment 
[30]. Following this, Lines et al. reported that long-term stable Hb levels within the 
target range was achieved by keeping a minimum interval of 2 months between ESA 
dose adjustments in the algorithm for the management of anemia with DA [31]. 
In this study, we made an overall decision on CERA dose adjustment in light of data 
from the previous year concerning Hb levels, ESA dose, and iron dose, in addition to 
various other data described above, with our priority being to maintain long-term stable 
Hb levels within the target range in future. As a result, Hb levels and CERA dose were 
both stably maintained during CERA administration (Fig. 1a, 1b), and the mean CERA 
dose adjustment frequency per 3 months was from 0.42 to 0.67 times, meaning that the 
dose was only adjusted once every 4.5 to 7.1 months (Fig. 1c). 
In the subgroup analysis (Fig. 1e, 1f, 1g), we found that in the low-dose group, the 
doses of both CERA and iron decreased over time following the switch to CERA, though 
Hb levels maintained stable. In the high-dose group, however, Hb levels, CERA and iron 
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doses all remained stable with no major changes. The mean initial dose conversion ratio 
from DA to CERA was 1.42  0.48 in the low-dose group, which was significantly higher 
than that in the high-dose group (1.16  0.18), but this difference quickly diminished 
following the switch and, after 12 weeks, it was no longer significant. However, the 
CERA dose in the low-dose group continued to decrease even after 12 weeks and, from 
32 weeks onwards, the difference between the two subgroups was significant. Because 
there was a transient increase in Hb levels in the low-dose group at the first month 
following the switch, the initially high dose conversion rate in that group may explain at 
least the initial decrease in CERA dose. With respect to the cause of the long-term 
CERA dose reduction in the low-dose group, the positive correlation between the dose 
reductions in CERA and iron during the 12 months following the switch suggested that 
continuous CERA Q2W administration may have resulted in the improvement of iron 
use efficiency, leading to the lower CERA dose and iron supplementation required for 
hematopoiesis. 
However, iron metabolism markers remained stable in the low-dose group throughout 
CERA administration, with no significant changes over time in either serum ferritin or 
TSAT. Further studies are required to investigate whether switching from DA to CERA 
Q2W may have a long-term effect on the dynamics of iron metabolism. 
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The limitations of this study are that it was a retrospective observational study that 
only included participants who were able to continue CERA Q2W administration for 12 
months after switching from DA. A prospective observational study comparing patients 
divided into two groups according to their responsiveness to ESA at baseline might 
more clearly establish the long-term advantages of CERA Q2W for anemia management 
in dialysis patients. Patients whose anemia could not be managed at a stable level using 
DA prior to switching to CERA were excluded from this study; therefore, further studies 
are required to establish whether the policies for CERA dose adjustment and iron 
replacement under CERA Q2W that had been used in this study are applicable to 
dialysis patients more generally. 
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Conclusions 
 
In a single-center retrospective cohort observational study of 33 Japanese 
maintenance hemodialysis patients with renal anemia, we found that stable Hb levels 
were maintained for 12 months, after patients switched from DA Q1W to CERA Q2W, at 
the mean dose conversion ratio of 1.24  0.33. An overall decision on CERA dose 
adjustment was made through taking account of past changes in Hb levels, ESA dose, 
and iron dose over the previous year, in addition to the assessment of weekly complete 
blood count data including Hb and monthly measurements of nutritional, inflammatory, 
and iron metabolism markers. As a result, the mean frequency of CERA dose 
adjustment in each 3-month period was maintained as low, with the dose adjusted once 
every 4.5 to 7.1 months, and this may have contributed to the maintenance of stable Hb 
levels over a 12-month period. A subgroup analysis showed that for the patients who 
had been given lower maintenance doses of DA, CERA dose decreased continuously over 
the 12 months following the switch, possibly because the efficiency of iron use increased 
over time during that period. 
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Tables 
 
Table 1  Baseline patient characteristics 
  (n=33) 
Age (years) 67.7±11.5 
Male/female 15/18 
Dialysis vintage (years) 9.3±7.9 
Primary disease 
 
  Diabetes mellitus 14 
  Glomerulonephritis 11 
  Nephrosclerosis 4 
  Polycystic kidney disease 1 
  Others 3 
Darbepoetin alfa dose (μg/week) 32.6±14.9 
Hb (g/dL) 10.6±0.6 
Serum ferritin (ng/mL) 47.9±30.1 
TSAT (%) 17.0±9.6 
Serum albumin (g/dL) 3.6±0.3 
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CRP (mg/dL) 0.16±0.36 
Kt/V 1.73±0.29 
  
Data are expressed as the mean ± standard deviation, or as the number. 
Hb, hemoglobin; TSAT, transferrin saturation; CRP, C-reactive protein. 
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Table 2  Temporal changes in parameters prior to and following ESA switching in all patients (n=33) 
  
3 Months 
prior 
Baseline Month 3 Month 6 Month 9 Month 12 
Hb (g/dL) 10.6±0.6 10.6±0.6 10.5±0.7 10.8±0.7 10.8±0.9 10.7±0.9 
Serum total protein (g/dL) 6.4±0.3* 6.3±0.4 6.3±0.4 6.4±0.4 6.3±0.4 6.3±0.4 
Serum albumin (g/dL) 3.6±0.3 3.6±0.3 3.5±0.3 3.6±0.3 3.6±0.3 3.6±0.3 
Cholinesterase (IU/L) 249±73 245±68 244±65 252±69* 251±73 248±66 
CRP (mg/dL) 0.21±0.57 0.16±0.36 0.13±0.26 0.13±0.27 0.29±0.96 0.16±0.25 
Serum ferritin (ng/mL) 46.2±43.2 47.9±30.1 43.9±35.0 48.1±30.4 53.5±41.9 62.8±76.9 
TSAT (%) 18.1±9.2 17.0±9.6 16.6±11.9 19.4±11.9 18.2±12.2 19.9±10.8 
Serum iron (μg/dL) 50±23 46±23 44±27 53±30 48±30 53±26 
33 
 
UIBC (μg/dL) 237±54 236±61 240±63 235±65 231±62 225±57 
PCR（g/kg/day） 0.86±0.16 0.87±0.15 0.86±0.11 0.87±0.18 0.85±0.13 0.86±0.19 
Kt/V 1.72±0.31 1.73±0.29 1.70±0.30* 1.73±0.31 1.71±0.29 1.74±0.30 
       
Data are expressed as the mean ± standard deviation. *p<0.05 vs. baseline.  
Hb, hemoglobin; CRP, C-reactive protein; TSAT, transferrin saturation; UIBC, unsaturated iron binding capacity; 
PCR, protein catabolism rate. 
 
34 
 
Legends 
 
Fig.1 
Temporal changes in Hb levels (a), CERA doses (b), the frequency of CERA dose 
adjustment (c) and iron doses (d) in all patients (n=33), and the results of the subgroup 
analysis (e, f, g) stratified by the DA dose prior to ESA switching into the higher-dose 
group (n=22) and lower-dose group (n=11). a Monthly changes in Hb levels prior to and 
following ESA switching. b Bi-weekly changes in CERA doses after switching from DA. c 
The frequency of CERA dose adjustment during every 3 months after switching from 
DA. d The mean weekly iron dose during 3 months prior to switching from DA and every 
3 months after switching from DA. e Monthly Hb levels prior to and following ESA 
switching (subgroup analysis). f Bi-weekly CERA doses after switching from DA 
(subgroup analysis). g The mean weekly iron dose during 3 months prior to switching 
from DA and every 3 months after switching from DA (subgroup analysis). All data are 
expressed as the mean ± standard deviation. *p<0.05 vs. baseline; BL, baseline 
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